Zhejiang Ausun Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Zhejiang Ausun Pharmaceutical has been growing earnings at an average annual rate of 36%, while the Pharmaceuticals industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 25.3% per year. Zhejiang Ausun Pharmaceutical's return on equity is 12%, and it has net margins of 31.9%.
Key information
36.0%
Earnings growth rate
33.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 25.3% |
| Return on equity | 12.0% |
| Net Margin | 31.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Zhejiang Ausun Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 855 | 273 | 120 | 80 |
| 31 Dec 23 | 817 | 254 | 118 | 78 |
| 30 Jun 23 | 852 | 273 | 142 | 86 |
| 31 Mar 23 | 822 | 258 | 122 | 78 |
| 31 Dec 22 | 765 | 235 | 118 | 67 |
| 30 Sep 22 | 718 | 213 | 110 | 72 |
| 30 Jun 22 | 665 | 186 | 94 | 64 |
| 31 Mar 22 | 631 | 173 | 84 | 64 |
| 31 Dec 21 | 570 | 146 | 83 | 69 |
| 30 Sep 21 | 537 | 131 | 76 | 57 |
| 30 Jun 21 | 485 | 117 | 66 | 50 |
| 31 Mar 21 | 474 | 110 | 69 | 52 |
| 31 Dec 20 | 409 | 87 | 63 | 51 |
| 30 Sep 20 | 406 | 72 | 71 | 61 |
| 30 Jun 20 | 389 | 78 | 69 | 67 |
| 31 Mar 20 | 329 | 70 | 60 | 55 |
| 31 Dec 19 | 308 | 56 | 57 | 48 |
| 30 Sep 19 | 293 | 62 | 49 | 41 |
| 30 Jun 19 | 257 | 51 | 50 | 36 |
| 31 Mar 19 | 252 | 50 | 48 | 37 |
| 31 Dec 18 | 244 | 44 | 45 | 34 |
| 30 Sep 18 | 255 | 54 | 48 | 34 |
| 30 Jun 18 | 266 | 52 | 32 | 44 |
| 31 Mar 18 | 251 | 43 | 38 | 35 |
| 31 Dec 17 | 240 | 53 | 41 | 30 |
| 30 Sep 17 | 217 | 55 | 38 | 19 |
| 30 Jun 17 | 216 | 62 | 53 | 0 |
| 31 Mar 17 | 197 | 58 | 48 | 0 |
| 31 Dec 16 | 199 | 57 | 48 | 0 |
| 31 Mar 16 | 259 | 62 | 65 | 0 |
| 31 Dec 15 | 263 | 61 | 65 | 0 |
| 31 Dec 14 | 201 | 22 | 74 | 0 |
| 31 Dec 13 | 121 | 16 | 31 | 0 |
Quality Earnings: 603229 has high quality earnings.
Growing Profit Margin: 603229's current net profit margins (31.9%) are higher than last year (31.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603229's earnings have grown significantly by 36% per year over the past 5 years.
Accelerating Growth: 603229's earnings growth over the past year (5.6%) is below its 5-year average (36% per year).
Earnings vs Industry: 603229 earnings growth over the past year (5.6%) exceeded the Pharmaceuticals industry 4.8%.
Return on Equity
High ROE: 603229's Return on Equity (12%) is considered low.